Last reviewed · How we verify
NCT03691012
Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer
trial testing Circulating tumour DNA testing in Ovarian Cancer in 118 participants. Status unknown.
31 December 2020
Quick facts
| Lead sponsor | Walter and Eliza Hall Institute of Medical Research |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 118 |
| Start date | 9 May 2017 |
| Primary completion | 31 December 2020 |
| Estimated completion | 9 May 2025 |
| Sites | 7 locations across United States, Australia |
Drugs / interventions tested
- Circulating tumour DNA testing
Conditions studied
- Ovarian Cancer — all drugs for Ovarian Cancer →
Sponsor
Walter and Eliza Hall Institute of Medical Research
Who can join
Adults 18 to 100, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To demonstrate that detectable ctDNA in peripheral blood following debulking of the primary tumour or following completion of adjuvant treatment for is associated with subsequent disease recurrence in stage I-IV epithelial, fallopian tube and primary peritoneal cancer (Ovarian Cancer)
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).
Chin RI, Chen K, Usmani A, Chua C, et al · · 2019 · cited 144× · PMID 30941670 · DOI 10.1007/s40291-019-00390-5 -
Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial Cancer.
Chen Q, Zhang ZH, Wang S, Lang JH. · · 2019 · cited 44× · PMID 31920340 · DOI 10.2147/ott.s227156 -
Prediction of the treatment response in ovarian cancer: a ctDNA approach.
Sharbatoghli M, Vafaei S, Aboulkheyr Es H, Asadi-Lari M, et al · · 2020 · cited 21× · PMID 33076944 · DOI 10.1186/s13048-020-00729-1 -
Engineering Multidimensional Evolutionary Forces to Combat Cancer.
McCoach CE, Bivona TG. · · 2019 · cited 14× · PMID 30992280 · DOI 10.1158/2159-8290.cd-18-1196
Verify or expand the search:
- PubMed search for NCT03691012
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ovarian Cancer
Currently open trials in the same condition.
- NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
- NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
- NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
- NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03691012 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Walter and Eliza Hall Institute of Medical Research
- Last refreshed: 9 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03691012.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing